Group 1 - The company, Fuhong Hanlin (02696), announced a revised and partially terminated agreement with KGBio to terminate exclusive licensing rights for products in regions outside of Indonesia [1] - The company has also amended its licensing agreement with Abbott to expand the licensing area and milestone payment terms for licensed products, including the regions previously terminated with KGBio [1] - The termination of the commercial collaboration with KGBio allows the company to grant exclusive commercialization rights for the licensed products in the newly added regions to Abbott, enhancing the company's international market reach and product recognition [1]

Core Viewpoint - The company has entered into a revised and partially terminated agreement with KGBio to end exclusive licensing rights for certain products in regions outside of Indonesia, while simultaneously expanding its licensing agreement with Abbott to include these newly available regions [1] Group 1: Agreement with KGBio - The company has amicably negotiated with KGBio to terminate the commercialization cooperation for licensed products in the KGBio termination regions [1] - The termination of the agreement allows the company to focus on expanding its licensing opportunities in other regions [1] Group 2: Agreement with Abbott - The company has revised its licensing agreement with Abbott to expand the licensing area and milestone payment terms for certain products [1] - This expansion includes the KGBio termination regions and other agreed countries or areas, enhancing the company's ability to commercialize its products internationally [1] - The strengthened collaboration with Abbott is expected to improve the accessibility and recognition of the company's products in overseas markets [1]